Biofourmis vs Qure.ai

Qure.ai has a disclosed valuation of $270M, while Biofourmis's valuation is not publicly available, making a direct size comparison difficult. Qure.ai employs 250 people.

Biofourmis has raised more in total funding at $465M, compared to Qure.ai's $160M — a gap of $305M. Combined, the two companies have completed 6 known funding rounds.

Biofourmis leads with an Awaira Score of 73/100, while Qure.ai sits at 70/100. That 3-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Biofourmis was founded by Kuldeep Singh in 2015. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.

Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.

Biofourmis got there first, launching in 2015 — that's 1 year of extra runway. Qure.ai didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Biofourmis has about 100-500 employees; Qure.ai has about 250. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Biofourmis and Qure.ai compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.